Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Jennifer Good, President and CEO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), recently sold 5,263 shares of the company’s common stock, amounting to $34,624. The transaction comes as Trevi, currently valued at $639 million, has seen its stock surge over 107% in the past six months according to InvestingPro data. The shares were sold at a weighted average price of $6.5789, with prices ranging from $6.55 to $6.60. Following this transaction, Good holds 213,313 shares directly. Notably, analysts maintain a bullish outlook on TRVI, with price targets ranging from $11 to $29.
Additionally, Good exercised stock options to acquire 5,263 shares at a price of $1.43 each, totaling $7,526. The options, initially granted in 2015, have fully vested. This transaction leaves Good with no remaining stock options to exercise. InvestingPro analysis shows Trevi maintains strong financial health with a current ratio of 10.41, indicating robust liquidity. Get access to 12 additional ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Trevi Therapeutics reported a net loss of $11.4 million for the fourth quarter of 2024, an increase from the $7.8 million loss in the same period of 2023. Despite the widened loss, the company slightly exceeded earnings per share expectations with a result of -0.11 compared to the forecasted -0.12. Analysts have maintained their confidence in Trevi Therapeutics, with Raymond (NSE:RYMD) James reiterating a Strong Buy rating and a $29 price target, Stifel maintaining a Buy rating with a $15 target, and H.C. Wainwright reaffirming a Buy rating with a $12.50 target. These ratings are supported by promising data from Trevi’s Haduvio trials, particularly in treating refractory chronic cough and idiopathic pulmonary fibrosis-associated chronic cough. The company is preparing for key Phase 2b CORAL study results expected in the second quarter of 2025, which are anticipated to be pivotal for the development of Haduvio. Trevi’s financial position remains strong, with cash reserves projected to sustain operations into the second half of 2026, allowing the company flexibility in its ongoing clinical trials and potential strategic partnerships. The upcoming presentation of new data at the American Thoracic Society 2025 conference is expected to further engage the medical community and increase visibility for Haduvio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.